Greg Calligaro

@catherinetom @SpotlightNSP Congratulations @catherinetom on an excellent article laying bare the gross inequity in global access for a lifesaving therapy for cystic fibrosis, and the rationale behind the court application by dynamic courageous patient advocate @cherivdw for compulsory registration in SA.

Still no reimbursement agreements 4 lifesaving drugs #Trikafta #Kaftrio in Spain, Netherlands, Poland, Russia, Turkey, Australia, New Zealand, S Africa, the Middle East … the list goes on. Time for @VertexPharma to get their lifesaving drugs to ALL that need them. CF won’t wait.

Strong statement from the South African Thoracic Society endorsing the benefits of vaccination and condemning recent unsubstantiated and dangerous attempts at misinformation. #SouthAfricanASP @WestCapeHealth @UCTHealthSci @graemein @TomScriba #GetVaccinatedNow #vaccineworks

Critical Statement on threats levelled at SA Health Products Regulatory Authority @MRCza @SAHPRA1 @ShabirMadh @FrancoisVenter3 @SAMedicalAssoc @fidssa1 @US_FDA @EMA_News @WHOAFRO @_AfricanUnion samrc.ac.za/media-release/…

Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS) thelancet.com/journals/lance… I have had lots of people asking me what we can do following the publication of ACCCOS. These are my top 3 thoughts;

Wouldn’t it be nice if every person who is currently stigmatising South Africa & Brazil, remembered that #SARSCoV2 is a virus which loves to mutate & that your beloved country may be the next in line through no fault of your own. #SARSCoV2 doing it’s own sweet thing. Globally...

@SkosanaDr Thanks for your interest in our paper. thelancet.com/journals/eclin…

The Moderna vaccine. Even 14 days after the first shot, you can see a separation of the treatment (orange) vs placebo (purple) groups, with them reporting a similar 95% reduction in new infections in vaccinated group to the Pfizer vaccine . This is a very effective vaccine.

Millennials are not lazy. That’s it. That’s my tweet #2020superinterns

The patient's story here is also our story.

Unconscionable that life-changing therapy exists for #cysticfibrosis but is unaffordable in most of the world. @VertexPharma - no patient should be left behind!

We are calling on Vertex to do the right thing. Grant Cystic Fibrosis children in all countries affordable access to CFTR Modulator therapies such as Trikafta, Symdeko, Kalydeco and Kaftrio. These therapies can Save our lives. #VertexSaveUs #VertexSaveMe #cfwarrior #NACFC2020

@MerandaCF Wish our patients with #cf in #SouthAfrica had access to these game-changing drugs. Tiered pricing structure for patients in LMICs urgently needed! @VertexPharma

Review of viral ARDS pathogenesis, how it informs evolving models of #COVID19, and how hallmarks of ageing explain the age-related morbidity and mortality of severe COVID-19 bit.ly/39Ca0c0

In an article published this week in @TheLancet's EClinicalMedicine, medical experts from @StellenboschUni and #UCT describe how they were able to successfully treat half of all their critically ill #COVID19 patients by using high-flow nasal oxygen: bit.ly/treatcovid1

Good morning. Evaluate every day need for antibiotics, if they can be stopped, deescalated, switched to orals. Every additional dose of antibiotics has the potential to cause serious harm in the present and in the future; seen and unseen. Be aware. Happy Wednesday 😀

asos.org.za/acccos/Documen… See our ACCCOS study statement currently submitted for peer review and publication. Hopefully informing practice in Africa going forward during the remainder period of this #COVID pandemic @BruceBiccard

Our experience with HFNO for severe #COVID19 at two public sector hospitals in Cape Town. @UCTHealthSci @StellenboschUni @UniversityCape

Congratulations @elmimuller !!!

Using test-based criteria for HCW infected with COVID-19 demonstrated prolonged PCR-positivity and was assocaited with an additional 4,097 lost workdays compared to time+symptom based criteria @ericashenoy cambridge.org/core/journals/…